Evercore ISI Group Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Aclaris Therapeutics with an Outperform rating and a price target of $22.
October 03, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group's Outperform rating and price target of $22 for Aclaris Therapeutics could potentially boost the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Evercore ISI Group's positive rating and price target for Aclaris Therapeutics could lead to increased investor interest and potentially boost the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100